João Bocas - The Wearables Expert ™ interviews Charles Michael Gibson, MD. CEO of Baim Institute for Clinical Research, (FKA…
GOT CANCER? A FASTING-MIMICKING diet may lead to positive changes in your metabolism and immune system. A new study from Milan (Italy) suggests…
Many dementia misdiagnoses are written in stone in charts, and then the patients are treated accordingly. Often, patients suffer from…
The FDA approves Aduhelm for the treatment of early Alzheimer's disease. Aduhelm targets brain plaque formation to slow the rate…
Cedar Health Research, located in Dallas and Irving, is currently enrolling candidates in two clinical trials to evaluate the safety…
If all goes well, thanks to artificial intelligence, we may soon have a new AI-synthesized drug capable of assisting OCD…
Finding a magic cure is a surefire way to get reelected in the middle of a global pandemic. The entire…
Early, in-hospital treatment with colchicine reduces the odds of future cardiovascular problems by 48% in people who have just survived…
The ‘AMBITION' trial, is designed to assess safety, tolerability, and pharmacokinetics of 75 mg CRV431, administered orally to F2 and…
CRV431 has exerted antifibrotic activity in a number of in vitro and in vivo studies conducted by independent research laboratories
This website uses cookies. Your continued use of the site is subject to the acceptance of these cookies. Please refer to our Privacy Policy for more information.
Read More